Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 28NSCLC 4Brain Neoplasms 4Lung Neoplasms 3Pancreatic Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-Small-Cell Lung 1Neoplasms, Second Primary 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma of Lung 1

Interventions

Amifostine 4Cisplatin 3Voriconazole 2Radiotherapy 2Paclitaxel 2Methotrexate 2Drug Therapy 2selinexor 1sargramostim 1pazopanib 1lometrexol 1icotinib 1glucarpidase 1camrelizumab 1bismuth tripotassium dicitrate 1apatinib 1Telbivudine 1Surgical Procedures, Operative 1Pregabalin 1Pharmaceutical Preparations 1Ofloxacin 1Nivolumab 1Metronidazole 1Levofloxacin 1Imatinib Mesylate 1Hyperthermic Intraperitoneal Chemotherapy 1Gefitinib 1Folic Acid 1Etoposide 1Esomeprazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Drug-Related Side Effects and Adverse Reactions × icotinib × Clear all
NCT01963195 2017-05-08

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

Anhui Medical University

Phase 2 Unknown
30 enrolled

Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡